A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients

Karl L. Womer, Colm C. Magee, Nader Najafian, John P. Vella, Edgar L. Milford, Mohamed H. Sayegh, Charles B. Carpenter

Research output: Contribution to journalArticle

Abstract

Oral tolerance is an important physiological mechanism of immune hyporesponsiveness to dietary antigens and the commensal flora of the gastrointestinal tract. Feeding of alloantigens, therefore, has the potential to suppress undesirable immune responses after transplantation. To date, there are no published reports on the effects of such an approach in human transplant recipients. In the present pilot study, we demonstrate complete suppression of baseline indirect alloreactivity in patients with chronic renal allograft dysfunction following the oral feeding of low (0.5 mg/d) but not higher (1.0 and 5.0 mg/d) doses of donor major histocompatibility complex (MHC) class II peptides. The regimen was well tolerated with no evidence for sensitization to the donor antigen. Our results indicate that oral feeding of low dose donor MHC peptide may represent a safe and effective therapy to suppress indirect alloreactivity in renal transplant recipients with chronic allograft dysfunction and warrants further clinical investigation.

Original languageEnglish (US)
Pages (from-to)754-759
Number of pages6
JournalClinical Transplantation
Volume22
Issue number6
DOIs
StatePublished - Nov 24 2008

Keywords

  • Active suppression
  • Chronic allograft nephropathy
  • Epitope spreading
  • Indirect allorecognition
  • Kidney transplantation
  • Oral tolerance

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients'. Together they form a unique fingerprint.

  • Cite this